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https://doi.org/10.101Hematopoietic stem cells (HSCs) are used clinically in bone marrow (BM) transplantation due
to their unique ability to reform the entire hematopoietic system. Recently, we reported that
HSCs are highly sensitive to valine, one of the three branched-chain amino acids (BCAAs) in
addition to isoleucine and leucine. Dietary depletion of valine could even be used as a condition-
ing regimen for HSC transplantation. Here, we report that HSCs are highly sensitive to the bal-
ance of BCAAs, with both proliferation and survival reduced by BCAA imbalance. However,
low but balanced BCAA levels failed to rescue HSC maintenance. Importantly, in vivo depletion
of all three BCAAs was significantly less toxic than depletion of valine only. We demonstrate
that BCAA depletion can replace valine depletion as a safer alternative to BM conditioning. In
summary, by determining HSC metabolic requirements, we can improve metabolic approaches
to BM conditioning. © 2018 ISEH – Society for Hematology and Stem Cells. Published by Elsev-
ier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/
licenses/by/4.0/)TaggedPBone marrow (BM) or hematopoietic stem cell (HSC)
transplantation (HSCT) is a potentially curative treat-
ment for a range of hematological disorders, such as
immunodeficiency diseases [1]. However, “space”
within the recipient’s HSC niche [2,3] must be first
made to allow donor HSCs to engraft [4]. Unfortu-
nately, the morbidity and mortality associated with tra-
ditional BM conditioning regimens, radiation and/or
chemotherapy, currently limit the application of HSCT
[5]. Recently, we reported that dietary valine depletion
could be used to condition mice for HSCT [6]. Impor-
tantly, this type of metabolic BM conditioning wasDivision of Stem Cell Therapy, Center for Stem Cell
ion Medicine, Institute of Medical Science, University
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6/j.exphem.2018.04.004entirely reversible, with mice returning to full health
and fertility after transplantation and return to a com-
plete diet. Here, we describe important optimization of
this novel conditioning approach for improved safety
and tolerance based on further characterization of the
metabolic sensitivity of HSCs.
TaggedPNearly 60 years ago, Harper [7] proposed that amino
acid imbalance could be a mechanism of disease. Valine
is a one of three branched-chain amino acids (BCAAs) in
addition to isoleucine and leucine. BCAA imbalance has
been suggested to cause cellular toxicity, including neuro-
toxicity [8]. Stimulated by these reports, we investigated
the sensitivity of HSCs to BCAA imbalance using ex vivo
HSC expansion cultures. Expansion of mouse CD34/
loKit+Sca1+Lineage (CD34-KSL) HSCs [9] was deter-
mined after a 7-day culture in Dulbecco’s modified
Eagle’s medium (DMEM)/F12-based self-renewal condi-
tions [10]. DMEM/F12 medium was used because it con-
tains approximately equimolar concentrations of BCAAs:by Elsevier Inc. This is an open access article under the CC BY license.
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isoleucine.
TaggedPWhen the concentration of valine was reduced to »10%
in this context (valine-low), we only mildly inhibited
HSC expansion (Figures 1A and 1B). However, when
valine was reduced to »10% while the concentration of
isoleucine/leucine (I/L) was simultaneously increased five-
fold (valine-low, I/L-high), HSC expansion was blocked
completely (Figures 1A and 1B). These results reproduced
our initial screening [6], which used medium containing a
similar BCAA imbalance. In contrast, increasing I/L con-
centrations fivefold in complete conditions (I/L-high)
increased HSC expansion (Supplementary Figure E1,
online only, available at www.exphem.org). Notably,
reducing all three BCAAs to »10% in BCAA-low condi-
tions (Figures 1A and 1B) only resulted in a modest, non-
statistically significant reduction in HSC expansion.
Through single-cell assays, we found that BCAA imbal-
ance (valine-low, I/L-high) blocked HSC expansion
through a combination of increasing cell death and inhibit-
ing proliferation (Figures 1C and 1D). However, whereas
BCAA-low conditions did not influence HSC proliferation
or survival significantly, it was not able to sustain in vivo
function of HSCs activity, as indicated by decreased
reconstitution capability of these cultured HSCs
(Figure 1E). We therefore conclude that BCAA imbalance
reduces HSC proliferation and survival, whereas low
valine results in poor HSC maintenance.
TaggedP o further investigate the translational potential of
these findings, we investigated the consequences of
BCAA imbalance on human cord blood-derived
CD34+CD38Lineage hematopoietic stem and progen-
itor cells (HPSCs). As seen with mouse HSCs, BCAA
imbalance (valine-low, I/L-high) caused greater toxic-
ity, with essentially no cells surviving the 7-day culture
(Figures 1F and 1G). However, whereas BCAA-low
conditions rescued mouse HSC expansion, it failed to
rescue human HSPC expansion (Figures 1F and 1G).
This is likely due to our previous finding that human
HSPCs are also sensitive to leucine depletion [6].
TaggedPOne concern with our initial proof-of-concept dem-
onstration of metabolic BM conditioning [6] was the
potential toxicity of dietary valine depletion. Although
the effects of this metabolic conditioning approach
were entirely reversible in mice after treatment (unlike
radiation conditioning), the conditioning process did
cause on-treatment side effects. Given that the imbal-
ance of amino acids (and particularly BCAAs) is asso-
ciated with systemic toxicities [8], we wondered
whether our new understanding that HSCs were depen-
dent of valine irrespective of BCAA balance could be
used to improve non-chemoirradiative HSCT. We ini-
tially compared the consequences of dietary valine and
BCAA depletion on hematopoiesis in mice. Consistent
with our in vitro data, a BCAA-free (BCAA) dietlargely mirror a valine-free (valine) diet, displaying
reduced phenotypic HSC frequencies within the BM
(Figure 2A) and peripheral blood (PB) whole blood
cell counts (Figure 2B).
TaggedPInterestingly, although we observed a reduction in
red cell blood counts after a valine diet, this anemia
was milder with a BCAA diet (Figure 2C). This sug-
gests erythropoiesis may also be sensitive to BCAA
imbalance and implies that the BCAA diet is better
tolerated. Our previous valine dieting experiments
had also been hampered by mortality after 4 weeks [6].
We therefore investigated the survival of mice on
valine and BCAA diets directly (Figure 2D). Mice
survived for a median of 49 days on the valine diet.
In contrast, a BCAA diet was much better tolerated
by mice, with all mice surviving >7 weeks and 70%
surviving 14 weeks. These data are also consistent with
the report that a valine diet caused neurotoxicity in
rats, but this was not observed after a BCAA diet
[8]. Combined, these data suggest that the use of a
BCAA diet displays better safety and tolerance com-
pared with a valine diet.
TaggedPFinally, we wanted to confirm that a BCAA diet
could be used as efficiently as a valine diet to condi-
tion the BM for HSCT. We conditioned NOD.Cg-
Prkdcscid Il2rgtm1Sug/ShiJic (NOG) mice [11] for 2
weeks and then transplanted 104 C57BL/6 (C57BL/
6NCrSlc) KSL cells before returning the diet to nor-
mal. Both BCAA and valine diets resulted in close
to 100% PB chimerism in the long term (Figure 2E). A
BCAA diet therefore affords comparable BM condi-
tioning for HSCT, but with reduced nonspecific toxic-
ity compared with a valine diet.
TaggedPIn summary, we have demonstrated that BCAA bal-
ance can resolve the sensitivity of HSCs to valine via
its influence on cell cycle progression, survival, and
influence on HSC maintenance. From these insights,
we have developed a second-generation metabolic BM-
conditioning regimen using BCAA depletion, which
displays reduced in vivo systemic toxicity compared
with valine depletion. These data provide an important
step toward optimizing safe and well-tolerated meta-
bolic BM-conditioning approaches for HSCT.
TaggedPWe hope this further understanding of the metabolic
requirements of HSCs will lead to successful transla-
tion of safe metabolic BM-conditioning regimens to
HSCT [12]. Metabolic BM conditioning may also be
useful for basic HSC research, particularly for model
animals in which radiation conditioning is challenging
[13]. Through understanding the roles of BCAA-
sensing mechanisms [1416] and BCAA metabolism
[17,18] in HSC maintenance, we may also be able to
develop pharmacological strategies for BM condition-
ing. Finally, it has been suggested recently that BCAA
metabolism regulates leukemic progression [19,20],
Figure 1. BCAA imbalance caused by low valine and high I/L blocks HSC expansion through reducing survival and inhibiting proliferation.
(A,B) Mouse BM CD34-KSL HSCs were expanded (40 cells/well) for 7 days in DMEM/F12-based media supplemented with 0.1% human serum
albumin, stem cell factor (SCF, 50 ng/mL), thrombopoietin (TPO, 50 ng/mL), and 1% S-clone SF-O3 medium supplement. Representative colony
images (4£magnification) are shown in (A) and average cell numbers per well in (B). (C,D) Single HSCs were monitored over 5 days in the
media described above. The percentage of empty wells in shown in (C). Estimated average number of hours per cell division event based on
total number of cells at day 5 in (D). Forty-eight cells were analyzed per condition. (E) Average donor PB chimerism § SEM from competitive
transplantation assays using 7-day cultured HSCs from (A) at 16 weeks after transplantation. C57BL/6 Ly5.1 HSCs were injected into irradiated
C57BL/6 Ly5.2 mice (5 mice/condition) alongside 106 Ly5.1/Ly5.2 whole BM competitor cells, as described previously [10]. All animal experi-
ments described herein followed guidance and approval from the Animal Care and Use Committee, Institute of Medical Science, University of
Tokyo, or the Administrative Panel on Laboratory Animal Care, Stanford University. (F,G) Human CD34+CD38Lineage HSPCs from umbili-
cal cord blood (kindly provided the Stanford Binns Cord Blood Program) were expanded (300 cells/well) for 7 days in DMEM/F12-based media
supplemented with 1% bovine serum albumin, SCF (50 ng/mL), TPO (50 ng/mL), FLT3L (50 ng/mL), interleukin-6 (IL-6, 20 ng/mL), IL-3
(20ng/mL), and 1% S-clone SF-O3 medium supplement, as described previously [6]. Representative colony images are shown in (F) and average
cell numbers per well § SEM (n = 5) are shown in (G). Statistically significant differences (one-way ANOVA) are denoted by asterisks: *p > 0.05,
**p > 0.01, ***p > 0.001. n.s.=not significant.
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Figure 2. Dietary BCAA depletion is a less toxic metabolic conditioning regimen for HSCT. (AC) C57BL/6 mice were fed a complete, valine, or
BCAA diet (Research Diet, Inc.). Average BM and PB parameters were determined (n = 5 mice/condition). (A) BM CD34-KSL frequency after 4 weeks.
(B) PB whole blood cell counts after 2 and 4 weeks. (C) PB red blood cell counts after 2 and 4 weeks. Statistically significant differences (one-way
ANOVA) are denoted by asterisks: *p > 0.05, **p > 0.01, ***p > 0.001. n.s.=not significant. (D) Survival of C57BL/6 mice on complete, valine, and
BCAA diets (10 mice/condition). Statistical testing was done using the logrank test (***p > 0.001). (E) NOG mice were fed complete, valine, or
BCAA diets for 2 weeks after an initial 48-hour fast and then injected with 104 (C57BL/6) BM KSL cells and the complete diet was restored gradually.
No mortality was observed during transplantation. Average donor PB chimerism § SEM at 16 weeks after transplantation (n = 45 mice per condition) is
shown.
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Supplementary Figure E1. (A) Mouse BM CD34¡KSL HSCs were expanded (40 cell/well) for seven days in DMEM/F12-based medias supple-
mented with 0.1% human serum albumin, SCF (50ng/mL), TPO (50ng/mL), and 1% S-clone SF-O3 medium supplement. (B) Human
CD34+CD38¡Lineage¡ HSPCs from umbilical cord blood were expanded (300 cells/well) for seven days in DMEM/F12-based medias supple-
mented with 1% BSA, SCF (50ng/mL), TPO (50ng/mL), FLT3L (50ng/mL) IL-6 (20ng/ml), IL-3 (20ng/ml), and 1% S-clone SF-O3 medium sup-
plement.
